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Abstract
Introduction
Acute kidney injury (AKI) requiring renal replacement therapy (RRT) is associated with high
mortality. The creatinine-based stage of AKI is considered when deciding to start or delay
RRT. However, creatinine is not only determined by renal function (excretion), but also by dilu-
tion (fluid balance) and creatinine generation (muscle mass). The aim of this study was to
explore whether fluid balance-adjusted creatinine at initiation of RRT is related to 28-day mor-
tality independent of other markers of AKI, surrogates of muscle mass and severity of disease.
Methods
We performed a post-hoc analysis on data from the multicentre CASH trial comparing citrate
to heparin anticoagulation during continuous venovenous hemofiltration (CVVH). To deter-
mine whether fluid balance-adjusted creatinine was associated with 28-day mortality, we
performed a logistic regression analysis adjusting for confounders of creatinine generation
(age, gender, body weight), other markers of AKI (creatinine, urine output) and severity of
disease.
Results
Of the 139 patients, 32 patients were excluded. Of the 107 included patients, 36 died at 28
days (34%). Non-survivors were older, had higher APACHE II and inclusion SOFA scores,
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lower pH and bicarbonate, lower creatinine and fluid balance-adjusted creatinine at CVVH
initiation. In multivariate analysis lower fluid balance-adjusted creatinine (OR 0.996, 95% CI
0.993–0.999, p = 0.019), but not unadjusted creatinine, remained associated with 28-day
mortality together with bicarbonate (OR 0.869, 95% CI 0.769–0.982, P = 0.024), while the
APACHE II score non-significantly contributed to the model.
Conclusion
In this post-hoc analysis of a multicentre trial, low fluid balance-adjusted creatinine at CVVH
initiation was associated with 28-day mortality, independent of other markers of AKI, organ
failure, and surrogates of muscle mass, while unadjusted creatinine was not. More tools are
needed for better understanding of the complex determinants of “AKI classification”, “CVVH
initiation” and their relation with mortality, fluid balance is only one.
Introduction
Acute kidney injury (AKI) in critically ill patients is an independent risk factor for increased
morbidity and mortality. Despite improved recognition and treatment, mortality rates remain
between 40 and 60% [1]. Nowadays, AKI is staged by the ratio of actual serum creatinine to
pre-admission serum creatinine (Risk, Injury, Failure, Loss, End stage renal disease (RIFLE),
Acute Kidney Injury Network (AKIN), Kidney Disease: Improving Global Outcomes (KDIGO)),
thereby defining three stages of AKI severity [2–5]. Several studies explored the relation between
creatinine-based criteria of AKI at initiation of continuous renal replacement therapy (CRRT)
and mortality. Bagshaw et al. found that a lower creatinine, was associated with high mortality
[6]. Recently, two randomized controlled trials evaluated the effect of creatinine-based criteria to
initiate CRRT on mortality using the KDIGO stage of AKI and found controversial results: either
a survival benefit for starting at a lower stage of AKI (stage 2) [7], or no difference in mortality
when starting at stage 3 (early) or later when complications developed [8]. Two observational
studies reported that a lower creatinine at initiation of CRRT had a poor prognosis [9, 10]. How-
ever, the use of AKI stage, as a marker for severity of AKI and initiation of RRT has several limi-
tations. Plasma creatinine concentration, the cornerstone of AKI staging, is not only determined
by renal excretion, but also by hemodilution (caused by fluid accumulation) and by creatinine
generation, e.g. by muscle mass. Lower creatinine levels due to fluid overload or low creatinine
generation therefore underestimate true renal function impairment in critically ill patients. In
none of the above mentioned studies creatinine was adjusted for fluid-balance [6–10].
The effect of fluid balance on AKI classification and outcomes was initially evaluated in a
post-hoc analysis of the Fluid and Catheter Treatment Trial [11]. The study showed that
patients who had AKI after adjustment for fluid balance (but not before) had worse outcomes
than patients who had no AKI before and after adjustment for fluid balance. The modulating
effect of fluid overload on the diagnosis of AKI using serum creatinine was recently evaluated
by Macedo et al. [12]. They concluded that dilution of serum creatinine by fluid accumulation
leads to underestimation of severity of AKI and delays the identification of a 50% increase in
serum creatinine in critically ill patients. They developed a formula to adjust serum creatinine
for fluid accumulation.
The aim of the present explorative study was to evaluate whether fluid balance-adjusted
serum creatinine at CRRT initiation is related to mortality independent of other markers of
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severity of AKI, surrogate markers of muscle mass (age, sex, race and body weight) and sever-
ity of disease.
Methods
We performed a post-hoc analysis of data from a multi-center randomized controlled trial,
comparing citrate and heparin anticoagulation during continuous venovenous hemofiltration
(CVVH) [13]. Mortality between groups was not different. The study included patients requir-
ing CVVH for AKI in 10 participating ICUs in the Netherlands. The study was performed in
accordance with the declaration of Helsinki. The study was registered at clinicaltrials.gov num-
ber NCT00209378. The ethical committee VU medical Center approved this study. The local
medical ethical committees of the participating centers approved this study. Written informed
consent was obtained from all participants or their legal representative.
Study population
Between April 2005 and March 2011, patients were prospectively screened for inclusion in the
CASH trial. The study included adult patients requiring CVVH for AKI and excluded patients
older than 80 years, patients with an increased bleeding risk, with a known heparin induced
thrombocytopenia (HIT) and patients needing therapeutic systemic anticoagulation. Patients
were randomized to receive heparin or citrate anticoagulation for CVVH in predilution mode,
with predilution replacement flow rates between 2000 and 4000 ml/h, according to local guide-
lines. For the present study, patients were post-hoc excluded when no creatinine at initiation
of CVVH was available, or when a documented diagnosis of intrinsic renal disease (such as
renal artery stenosis, diabetic nephropathy, nephrotic syndrome or nephrosclerosis) was docu-
mented in the medical record. The reason to exclude these patients was that the cause of wors-
ening renal function could have been related to the underlying renal disease and not to critical
illness-related AKI. The diagnosis of AKI was made by the attending physician and the deci-
sion to initiate CVVH was based on the local protocol. Data were collected using the hospital
patient data management system.
Data collection
The following baseline data were collected: age, gender, weight and race as surrogates for mus-
cle mass, reason for ICU admission and cause of AKI (presumed as ischemic, septic or other/
toxic). At initiation of CVVH the following data were obtained: number of days at ICU before
CVVH initiation, cumulative fluid balance 3 days prior to initiation, diuresis 24 hours prior to
initiation, severity scores: APACHE (Acute physiology and Chronic Health Evaluation) II
score at ICU admission and SOFA (Sequential Organ Failure Assessment) score at CVVH ini-
tiation, creatinine at ICU admission (μmol/L), creatinine at initiation of CVVH (μmol/L). Cre-
atinine corrected for 3 day cumulative fluid balance was calculated according to the formula
defined by Macedo et al. [12]. Adjusted creatinine = initiation creatinine x ((hospital admis-
sion weight (kg) x 0.6 + ∑ (3 day cumulative fluid balance(L)))/ (hospital admission weight x
0.6)). The KDIGO stage at initiation was calculated using only the delta creatinine criteria
according to the KDIGO guidelines [2]. Unfortunately no pre-morbid creatinine was available
in this post-hoc analysis. We therefore used admission creatinine as baseline creatinine. When
patients were admitted with a single high creatinine and need of direct RRT, the attending
physician diagnosed AKI, when there was no history of chronic kidney disease and the patient
also had low urine output and other uremic symptoms. The initiation of RRT classified these
patients directly to KDIGO 3 [5].
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Endpoints
The primary endpoint was mortality at 28 days after CVVH initiation.
Statistical analysis
Variables were tested for normal distribution using the Kolmogorov-Smirnov test. Normally
distributed variables are expressed as mean (standard deviation), non-normally distributed
variables as median [interquartile range], and categorical data as number and percentage.
Unpaired Student’s t-test, Mann-Whitney-U test, Chi-square test or Fisher exact test was used,
where appropriate. Statistical significance was defined as p< 0.05.
To determine the association between fluid balance-adjusted serum creatinine and 28-day
mortality, logistic regression analysis was performed using backward stepwise likelihood ratio
including a maximum of n/10 variables choosing those variables that had a p<0.10 in univari-
ate analysis as confounders [14], including fluid balance because of its known association with
mortality [15, 16]. For diuresis, a z-score was calculated to obtain the OR for the change per
standard deviation in logistic regression. A p-value of 0.10 was used for entry and removal.
ROC curve analysis was used to define the cut-off value of fluid balance-adjusted creatinine
at CVVH initiation with best prediction for 28-day mortality in MedCalc1, version 15.6.1 using
the Youden index. This cut-off value was used to plot Kaplan Meier curves comparing the time to
survival between patients with low adjusted CVVH initiation creatinine to patients with high
adjusted CVVH initiation creatinine. The log-rank test was used to demonstrate differences.
Results
Flowchart
Of the 139 patients included in the CASH trial, 32 patients were excluded, 13 because of a his-
tory of intrinsic renal disease, 5 patients because there was no creatinine available at the day of
CVVH initiation and 14 patients because fluid balance was not available, so creatinine could
not be corrected for fluid balance. In 7 patients bicarbonate was not available, these additional
7 patients were not included in the multivariate analysis (Fig 1). Altogether, 107 patients were
included in the primary analysis and 100 patients in the multivariate analysis.
Patient characteristics according to 28-day outcome
Thirty-six out of the 107 patients (34%) did not survive at day 28. Patients who died were older
(72 [15] vs. 64 [15] years, p = 0.016), had higher APACHE II scores (25 (9) vs. 22 (7),
p = 0.043), lower bicarbonate (17.8 (4.3) mmol/L vs. 20.4 (4.1) mmol/L, p = 0.005), lower creat-
inine (278 (122) μmol/L vs. 347 (155) μmol/L, p = 0.022), and a lower fluid balance-adjusted
creatinine at initiation (313 (132) μmol/L vs. 388 (168) μmol/L, p = 0.022) compared to
patients alive at 28 days. Urine output, KDIGO stage, fluid balance, gender, weight, admission
creatinine, reason for ICU admission, days in the ICU, predilution dose and cause of AKI,
were not significantly different between groups. Baseline characteristics are shown in Table 1.
Relation between fluid balance-adjusted creatinine at CVVH initiation and
28-day mortality
To determine the association between fluid balance-adjusted creatinine and 28-day mortality,
variables that were potentially associated with mortality were first tested in univariate logistic
regression analysis. In this analysis lower bicarbonate (OR 0.853, 95% CI 0.758–0.960,
p = 0.008), lower creatinine at CVVH initiation (OR 0.996, 95% CI 0.993–1.000, p = 0.026),
Fluid balance-adjusted creatinine at CVVH initiation and mortality
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and lower fluid balance-adjusted creatinine at initiation (OR 0.997, 95% CI 0.994–1.000,
p = 0.026) were associated with mortality (Table 2). The relation with APACHE score tended
to significance (OR 1.058, 95% CI 1.000–1.119, p = 0.050).
Subsequently, logistic regression was performed including both creatinine and fluid bal-
ance-adjusted creatinine, APACHE II score, bicarbonate and fluid balance known to be associ-
ated with mortality [15, 16]. APACHE score was included as marker of severity of disease and
not SOFA score, because of the lower p-value of APACHE in univariate analysis. Age was not
included because age is a component of the APACHE score. After covariate adjustment lower
fluid balance-adjusted initiation creatinine (OR 0.996, 95% CI 0.993–0.999, p = 0.019), but not
unadjusted creatinine (lost in second step, first step: OR 1.021, 95% CI 0.987–1.056, p 0.228),
remained independently associated with 28-day mortality together with lower bicarbonate
(OR 0.869, 95% CI 0.769–0.982, p = 0.024), while APACHE II score non-significantly contrib-
uted to the model (Table 3).
To determine the cut-off value of the adjusted creatinine at initiation with the best associa-
tion with 28-day mortality, ROC-curve analysis was performed. In this analysis, a fluid bal-
ance-adjusted creatinine of 361 μmol/L appeared to be associated best with 28-day mortality.
Kaplan Meier survival curve analysis showed a significant difference between survival
curves for patients with CVVH initiation at an adjusted creatinine below 361 μmol/L and
Fig 1. Flowchart of included and excluded patients.
https://doi.org/10.1371/journal.pone.0197301.g001
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those equal to or above 361 μmol/L (log-rank p = 0.002) (Fig 2). Patients with CVVH initiation
at lower fluid balance-adjusted creatinine levels than 361 μmol/L had poorer survival.
Discussion
Key findings
In this post-hoc analysis of the database of a prospective randomized controlled multi-center
trial, we found that lower fluid balance-adjusted creatinine at initiation of CVVH was indepen-
dently associated with higher 28-day mortality while unadjusted creatinine (after covariate
correction) and KDIGO staging were not. This association was independent of muscle mass-
related confounders of creatinine (age, body weight, race), markers of severity of AKI
Table 1. Baseline characteristics of cohort, according to 28-day outcome.
Alive at 28 days, n = 71 Dead at 28 days, n = 36 P-value
Age, years 64 [15] 72 [15] 0.016
Male gender, nr (%) 50 (70) 22 (61) 0.332
Race, white, nr (%) 47 (64) 23 (64) 0.813
Weight, kg 83 [24] 86 [28] 0.789
Reason ICU admission, nr (%)
Circulatory failure 14 (20) 9 (25) 0.636
Respiratory failure 33 (46) 16 (44)
Trauma 3 (4) 1 (3)
Post CPR 2 (3) 3 (8)
Post-operative 19 (27) 7 (20)
Cause of acute kidney injury, nr (%)
Sepsis 31 (44) 14 (39) 0.731
Ischemic 38 (53) 20 (56)
Other 2 (3) 2 (5)
Creatinine admission, μmol/L 121 [110] 118 [168] 0.275
APACHE II 22 (7) 25 (9) 0.043
SOFA score 10 [5] 11 (4) 0.130
ICU admission before CVVH, days 2 [4] 3 [5] 0.594
Potassium, mmol/L 4.7 (0.8) 4.7 (0.7) 0.822
pH 7.29 (0.11) 7.25 (0.11) 0.090
Bicarbonate, mmol/L 20.4 (4.1) 17.8 (4.3) 0.005
At start CRRT
Cumulative fluid balance 3 days before start, ml 5556 [6484] 7102 (6142) 0.609
Diuresis in 24 hr prior to CVVH, ml 341 [851] 410 [1043] 0.617
Creatinine start CVVH, μmol/L 347 (155) 278 (122) 0.022
Fluid balance-adjusted creatinine at start, μmol/L 388 (168) 313 (132) 0.022
Predilution dose, ml/kg/hr 22 (5) 21 (6) 0.751
KDIGO stage, nr (%): 71 (100) 36 (100) 0.541
KDIGO 1 10 (14) 6 (17)
KDIGO 2 14 (20) 10 (28)
KDIGO 3 47 (66) 20 (55)
Mean (standard deviation) for normally distributed variables, median [interquartile range] for non-normally
distributed variables, number (percentage) when appropriate; CPR, cardiopulmonary resuscitation; APACHE II,
acute physiology and chronic health evaluation score; SOFA, sequential organ failure assessment; CVVH continuous
venovenous hemofiltration, KDIGO, kidney disease: improving global outcomes.
https://doi.org/10.1371/journal.pone.0197301.t001
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(bicarbonate, urine output, creatinine, KDIGO criteria) and severity of disease. The optimal
cut-off value in the present population for a fluid balance-adjusted creatinine was 361 μmol/L.
Mortality was higher in the patients in whom CVVH was initiated at a fluid balance-adjusted
creatinine below 361 μmol/L.
The interpretation of low fluid balance-adjusted creatinine is complex because creatinine is
a marker of the balance between creatinine generation (muscle mass) and creatinine excretion
(renal function). Low serum creatinine can therefore be considered as a low muscle mass or as
an earlier stage of AKI. The presently found relation may therefore indicate that either initia-
tion of CRRT at an earlier stage of AKI or low muscle mass at CRRT initiation are associated
with higher mortality, or both.
The role of fluid balance
Apart from muscle mass and severity of AKI, fluid overload is an important confounder for
mortality. Fluid overload is a dual confounder. Fluid overload itself is a severe complication of
Table 2. Univariate logistic regression analysis of variables associated with 28 day mortality.
OR 95% CI p-value
Age, years 1.039 1.000–1.081 0.053
Male gender 0.660 0.284–1.532 0.333
Race, white 0.903 0.390–2.091 0.813
Weight, kg 1.010 0.994–1.026 0.210
Creatinine at start CVVH, μmol/L 0.996 0.993–1.000 0.026
Cumulative fluid balance 3 days before start CVVH 1.000 1.000–1.000 0.382
Apache II 1.058 1.000–1.112 0.050
SOFA day 0 1.113 0.986–1.256 0.084
pH 0.035 0.001–1.761 0.093
Bicarbonate, mmol/L 0.853 0.758–0.960 0.008
Diuresis (z-score) 1.121 0.727–1.728 0.605
Fluid balance-adjusted creatinine at start, μmol/L 0.997 0.994–1.000 0.026
KDIGO stage
KDIGO 1 1 0.543
KDIGO 2 1.190 0.325–4.356 0.792
KDIGO 3 0.790 0.227–2.216 0.554
APACHE II, acute physiology and chronic health evaluation score, OR, Odds ratio, SOFA, sequential organ failure
assessment, KDIGO, kidney disease: improving global outcomes. For continuous variables the odds ratios are per
unit increase. For diuresis, Z-transformation was performed; this odds ratio is per standard deviation increase.
https://doi.org/10.1371/journal.pone.0197301.t002
Table 3. Multivariate logistic regression analysis of variables associated with 28-day mortality.
OR 95% CI p-value
APACHE II score 1.060 0.994–1.129 0.075
Bicarbonate, mmol/L 0.869 0.769–0.982 0.024
Fluid balance-adjusted creatinine start, μmol/L 0.996 0.993–0.999 0.019
OR, Odds ratio. The odds ratios are per unit increase.
Variables included: unadjusted creatinine, cumulative fluid balance, APACHE II score, Bicarbonate, adjusted
creatinine.
Variables removed: step 2: unadjusted creatinine was lost, step 3: cumulative fluid balance was lost
https://doi.org/10.1371/journal.pone.0197301.t003
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critical illness and independently associated with worse outcome, especially in patients with
AKI [15–18]. Furthermore, fluid overload dilutes serum creatinine and thereby underesti-
mates the severity of AKI and delays its diagnosis [12]. In a post-hoc analysis of the ARDS net-
work trial, patients who met the criteria for AKI after correction for fluid balance (and not
before) had a greater mortality than those who did not meet AKI criteria (before and after cor-
rection) and those who had AKI before but not after adjustment for fluid balance [11]. In
another study, patients in whom AKI was diagnosed only after adjustment for fluid balance
had higher mortality than patients without AKI [19]. To account for these dual effects of fluid
balance, we both adjusted creatinine for fluid balance and added fluid balance as an indepen-
dent factor in the multivariate logistic regression analysis.
Creatinine generation
Previous studies have shown an association between reduced creatinine generation during
hemodialysis [20], low serum creatinine at ICU admission (< 30 μmol/L) and low peak plasma
creatinine concentrations (< 60 μmol/L) with mortality [21, 22]. That low creatinine may
reflect reduced muscle mass has been demonstrated by Baxmann et al. using cystatin C as a
marker of renal function [23]. To adjust for the confounding of serum creatinine by low mus-
cle mass, we added surrogates for muscle mass in our multivariate regression analysis. Age is
one of the determinants of the APACHE II score and therefore covered by adding APACHE II
score in the multivariate analysis. Age has dual effects. A higher age is associated with higher
mortality per se, while on the other hand muscle mass declines with aging. Body weight, gen-
der and race were not included because we found no association with 28-day mortality in uni-
variate analysis. We do however admit that the present correction for confounders of muscle
mass is insufficient. Low body weight does not necessarily implicate low muscle mass and high
body weight may be associated with low muscle mass (sarcopenic obesity). Furthermore, the
relation between high age and low muscle mass is not straightforward. Thus, whether the
Fig 2. 28-day survival curves according to the optimal fluid balance-adjusted creatinine at initiation of CVVH.
https://doi.org/10.1371/journal.pone.0197301.g002
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present results suggest that low muscle mass at CVVH initiation is associated with increased
mortality cannot be excluded.
Creatinine excretion
Serum creatinine is primarily conceived as a marker of renal excretory function and the differ-
ent AKI classifications are based on this concept. Remarkably, while low fluid balance-adjusted
creatinine was associated with mortality, neither unadjusted creatinine nor the stage of AKI
according to the KDIGO criteria was associated with mortality in this study. The determina-
tion of AKI stage was as reliable as possible because we excluded patients with missing creati-
nine before initiation of CVVH. As recently discussed by Chawla et al. it is important to
consider the timeframe of development of kidney injury to accurately classify these patients
[5]. However, because premorbid creatinine values were not available we used baseline instead
of pre-admission creatinine which can be conceived as limitation. In patients with a high
admission creatinine and direct need of RRT the attending physician diagnosed AKI (and not
CKD), based on clinical data. These patients were staged as KDIGO 3, because of immediate
initiation of RRT. Nevertheless, neither KDIGO nor the previous AKI classifications (RIFLE,
AKIN) consider the confounding of fluid balance.
Even when our results would suggest that initiation of CRRT at an earlier stage of AKI is
associated with higher mortality, the translation of these results to clinical practice is difficult.
In the present study, timing was left to the considerations of the physician in charge and it is
well known that CRRT is initiated at an earlier stage of AKI in the most severely ill patients
with hemodynamic instability, severe fluid overload or severe acidosis. Low bicarbonate was
an independent predictor of mortality in our study. Thus, the stage of AKI will never be the
sole criterion used to decide when to initiate CRRT in daily practice, the severity of illness and
renal and non-renal complications like fluid overload and acidosis are always considered. Ran-
domized controlled trials should account for this confounding.
Timing of CRRT using creatinine based criteria
The results of studies investigating timing of CRRT using creatinine based definitions are con-
troversial. Two systematic reviews cautiously suggested early CRRT initiation might be associ-
ated with better survival [24, 25]. However, these reviews were mainly based on low quality
heterogeneous studies. In a recently published randomized controlled trial in surgical patients,
initiation of CRRT at a lower creatinine (at KDIGO stage 2) was associated with lower mortal-
ity [7]. In contrast, a multicenter randomized controlled trial including patients with AKI
requiring mechanical ventilation or catecholamine infusion and without potentially AKI-
related life-threatening complications, found no difference in mortality between early
(KDIGO stage 3) and late initiation of RRT (when a conventional indication developed, after
diagnosing KDIGO stage 3) [8]. Similarly, a multicenter randomized feasibility trial found no
difference in mortality between early (within 12 hours after KDGIO stage 2) and late initiation
of RRT (when a conventional indication developed, after 12 hours reaching KDIGO stage 2)
either [26]. In the two latter trials, serum creatinine concentration at initiation of RRT was not
different between groups, and a substantial proportion of late patients did not receive RRT
because of dying or renal recovery. In contrast and in agreement with our results, two observa-
tional studies reported that a lower creatinine at initiation of CRRT was associated with higher
mortality [9, 10]. Recently two meta-analysis of high quality trials analyzed the impact of early
or late RRT initiation on outcome [27, 28]. After exclusion of studies reporting incomplete
baseline demographic data, studies without severity of illness assessment or studies with differ-
ences between cohorts at baseline, no survival benefit for early RRT initiation was found,
Fluid balance-adjusted creatinine at CVVH initiation and mortality
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supporting the importance of considering severity of disease when initiating CRRT. However,
none of the previous studies on timing, using creatinine as a compound of AKI stage or as a
solitary value, was adjusted for fluid balance. In the present study, we corrected for disease
severity and baseline characteristics, as well as for the non-renal confounders of creatinine, for
other markers of timing and for severity of disease, suggesting that low fluid balance-adjusted
creatinine could partially be interpreted as a marker of early timing of CRRT, and that, if this
were the case, early timing in this population was associated with mortality.
In contrast to previous studies, urinary output [21, 29] and days in ICU [6] were not related
to mortality in our population. Urinary output may be confounded by the use of diuretics and
oliguria does not necessarily implicate the presence of AKI [30].
Strengths and limitations
Important limitations of our study are the small sample size, limiting its statistical power. Fur-
thermore, the initiation of CVVH was not protocollized and was therefore biased. CRRT
might have been started earlier in the sicker patients explaining the higher mortality. More-
over, this study was not designed to evaluate fluid balance-adjusted creatinine. Patients who
needed systemic anticoagulation or had an otherwise increased risk of bleeding were excluded
in the CASH trial. As a result, we included less surgical patients and less patients with septic
AKI limiting the generalizability of our results. The database could, however, be used because
mortality between randomized groups was not different [13]. Unfortunately we had no data
on fluid balance more than three days prior to CRRT initiation. However, median stay in the
ICU was 2 days, thus for the majority of patients fluid balance from admission was available.
Furthermore, fluid balance may not precisely estimate fluid status, because part of the fluids
may be lost by perspiration or wounds. Also we did not have an independent measure of mus-
cle mass and had no data on premorbid creatinine. Finally, due to missing values, 7 patients
were excluded in the multivariate analysis. Nevertheless, our cohort is comparable to other
studies regarding disease severity, indicated by SOFA and APACHE II scores, age, vasopressor
dependency and proportion of mechanically ventilated patients [6, 31, 32]. Altogether, the
present study can only signal the pitfalls related to the interpretation of serum creatinine being
more than a marker of renal function [33].
Our study has several strengths. The use of fluid balance-adjusted creatinine to stage AKI is
unique in the available literature, and strongly recommended since recent studies showed
underestimation and misclassification of AKI if uncorrected creatinine is used [11, 12, 19].
Confounding is further minimized, because we adjusted creatinine for surrogate markers of
muscle mass, such as age, body weight and race. Despite these adjustments, the relation
between low creatinine and mortality as shown in our study insufficiently differentiates
between an earlier initiation of CVVH, a low muscle mass or both as risk factors for dying in
this population.
Conclusions
In conclusion, in this post-hoc analysis of a multicenter study we found that a low fluid bal-
ance-adjusted creatinine at initiation of CVVH was associated with increased 28-day mortality
independent of surrogates of muscle mass and severity of organ failure, while unadjusted cre-
atinine and KDIGO stage were not. Because we only used surrogates for muscle mass and fluid
status, the present study insufficiently differentiates whether a lower muscle mass or earlier ini-
tiation of CVVH or both are associated with mortality. Our results cannot be translated to clin-
ical practice, but are hypothesis generating. They suggest that future studies on determinants
of mortality should take fluid balance into account when investigating AKI stage as a criterion
Fluid balance-adjusted creatinine at CVVH initiation and mortality
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for timing of CRRT, include better markers of muscle mass such as bioimpedance analysis,
and account for severity of disease and acidosis.
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